LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON (IMNN), Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that ...
Elicio Therapeutics received FDA feedback supporting ELI-002's Phase 3 study design; Phase 2 analysis results expected in H1 2025. Elicio Therapeutics announced positive feedback from the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback